###begin article-title 0
Oncogenic BRAF Regulates Melanoma Proliferation through the Lineage Specific Factor MITF
###end article-title 0
###begin p 1
Conceived and designed the experiments: CW TB RM. Performed the experiments: CW SR HP HP TB. Analyzed the data: CW SR RM. Wrote the paper: CW RM.
###end p 1
###begin p 2
###xml 822 826 822 826 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MITF</italic>
The Microphthalmia-associated transcription factor (MITF) is an important regulator of cell-type specific functions in melanocytic cells. MITF is essential for the survival of pigmented cells, but whereas high levels of MITF drive melanocyte differentiation, lower levels are required to permit proliferation and survival of melanoma cells. MITF is phosphorylated by ERK, and this stimulates its activation, but also targets it for degradation through the ubiquitin-proteosome pathway, coupling MITF degradation to its activation. We have previously shown that because ERK is hyper-activated in melanoma cells in which BRAF is mutated, the MITF protein is constitutively down-regulated. Here we describe another intriguing aspect of MITF regulation by oncogenic BRAF in melanoma cells. We show oncogenic BRAF up-regulates MITF transcription through ERK and the transcription factor BRN2 (N-Oct3). In contrast, we show that in melanocytes this pathway does not exist because BRN2 is not expressed, demonstrating that MITF regulation is a newly acquired function of oncogenic BRAF that is not performed by the wild-type protein. Critically, in melanoma cells MITF is required downstream of oncogenic BRAF because it regulates expression of key cell cycle regulatory proteins such as CDK2 and CDK4. Wild-type BRAF does not regulate this pathway in melanocytes. Thus, we show that oncogenic BRAF exerts exquisite control over MITF on two levels. It downregulates the protein by stimulating its degradation, but then counteracts this by increasing transcription through BRN2. Our data suggest that oncogenic BRAF plays a critical role in regulating MITF expression to ensure that its protein levels are compatible with proliferation and survival of melanoma cells. We propose that its ability to appropriate the regulation of this critical factor explains in part why BRAF is such a potent oncogene in melanoma.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 154 157 154 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Hanahan1">[1]</xref>
###xml 320 323 320 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Garraway1">[2]</xref>
###xml 592 595 592 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Davies1">[3]</xref>
###xml 597 602 597 602 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 636 639 636 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Wan1">[4]</xref>
###xml 680 683 680 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Wellbrock1">[5]</xref>
###xml 748 751 748 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Hingorani1">[6]</xref>
###xml 753 756 753 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Karasarides1">[7]</xref>
###xml 758 763 758 763 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 807 815 807 815 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 861 868 861 868 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 868 871 868 871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Sharma1">[8]</xref>
###xml 940 947 940 947 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 947 950 947 950 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Karasarides1">[7]</xref>
###xml 952 955 952 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Hoeflich1">[9]</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human cancers arise through a multistage process, driven in part by accumulated genetic aberrations that stimulate cancer cell proliferation and survival [1]. Many of these changes, such as the mutations that activate oncogenes, are restricted to particular cell lineages and so are linked to particular types of cancer [2]. An example of this is seen with BRAF, a serine/threonine specific protein kinase that is mutated in 50-70% of spontaneous cutaneous melanomas. The most common mutation in melanoma (over 90% of cases) is a glutamic acid for valine substitution at position 600 (V600E) [3]. V600EBRAF is activated almost 500 fold [4], it transforms immortalised melanocytes [5], and it stimulates proliferation and survival in melanoma cells [6], [7]. V600EBRAF also stimulates melanoma cell invasion in vitro and is important for tumour neo-angiogenesis in vivo[8]. Furthermore, inhibition of oncogenic BRAF induces tumour shrinkage in vivo[7], [9]. These findings show that oncogenic BRAF controls many aspects of melanoma cell biology and yet it is currently unclear why BRAF is such a potent oncogene in the melanocyte lineage.
###end p 4
###begin p 5
###xml 380 384 380 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Levy1">[10]</xref>
###xml 512 517 512 517 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">INK4a</sup>
###xml 525 528 525 528 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cip</sup>
###xml 528 532 528 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Loercher1">[11]</xref>
###xml 534 538 534 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Carreira1">[12]</xref>
###xml 724 728 724 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Wellbrock2">[13]</xref>
###xml 818 822 818 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Hoek1">[14]</xref>
###xml 898 902 898 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Salti1">[15]</xref>
###xml 903 907 903 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Zhuang1">[17]</xref>
###xml 1148 1152 1148 1152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Wellbrock2">[13]</xref>
###xml 889 897 <span type="species:ncbi:9606">patients</span>
Another protein that is important in melanoma is the basic helix-loop-helix leucine zipper transcription factor MITF (microphthalmia-associated transcription factor). MITF is considered to be the "master regulator of melanocytes" because it is essential for melanoblast survival and melanocyte lineage commitment. It regulates expression of melanogenic enzymes such as tyrosinase [10], and contributes to melanocyte differentiation by triggering cell cycle exit through induction of the cell cycle inhibitors p16INK4a and p21Cip[11], [12]. We have previously shown that the differentiation functions of MITF occur at high protein concentrations, and accordingly, high levels of MITF are anti-proliferative in melanoma cells [13]. In agreement with this, low levels of MITF protein are found in invasive melanoma cells [14] and are associated with poor prognosis and disease progression in patients [15]-[17]. These data suggest that MITF must be down-regulated for melanoma progression and consistent with this, we have shown that in melanoma cells oncogenic BRAF suppresses MITF protein levels through ERK-mediated phosphorylation and degradation [13].
###end p 5
###begin p 6
###xml 208 212 208 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDK2</italic>
###xml 217 222 217 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL-2</italic>
###xml 236 240 236 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Du1">[18]</xref>
###xml 242 246 242 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-McGill1">[19]</xref>
###xml 265 269 265 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MITF</italic>
###xml 336 340 336 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Garraway2">[20]</xref>
Despite all the evidence suggesting that MITF must be down-regulated for melanoma progression, MITF expression is essential for proliferation and survival of melanoma cells because it regulates genes such as CDK2 and BCL-2 respectively [18], [19]. Furthermore, the MITF gene is amplified in 10-15% of melanomas in which BRAF is mutated [20], supporting the view that continued expression of MITF is essential in melanoma cells.
###end p 6
###begin p 7
###xml 646 650 646 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MITF</italic>
These observations show that the connection between MITF and melanoma development is complex. They also suggest that the interaction between oncogenic BRAF and MITF is more complex than previously reported and this prompted us to examine the interaction between these important proteins in more detail. Here we describe a new aspect of MITF regulation by oncogenic BRAF. We show that BRAF induces MITF transcription through the MEK/ERK cascade and the transcription factor BRN2. Thus, we propose that oncogenic BRAF down-regulates the MITF protein by targeting it for degradation in an ERK-dependent manner, but then counters this by stimulating MITF transcription in a BRN2-dependent manner. Through these opposing mechanisms, oncogenic BRAF executes exquisite control over MITF expression, ensuring that the protein levels are permissive for melanoma cell survival and proliferation.
###end p 7
###begin title 8
Results
###end title 8
###begin title 9
MITF expression is dependent on oncogenic BRAF in melanoma cells
###end title 9
###begin p 10
###xml 121 125 121 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Hemesath1">[21]</xref>
###xml 127 131 127 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Wu1">[22]</xref>
###xml 348 352 348 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Wellbrock2">[13]</xref>
###xml 361 370 361 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002734.s001">Figure S1</xref>
###xml 603 612 603 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g001">Figure 1A</xref>
###xml 752 761 752 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g001">Figure 1A</xref>
###xml 936 945 936 945 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g001">Figure 1A</xref>
Previous studies have shown that ERK phosphorylates MITF and targets it for degradation in a proteasome-dependent manner [21], [22]. We have gone on to show that as a consequence of ERK being constitutively activated in melanoma cell lines expressing oncogenic BRAF, MITF protein levels are lower in mutant BRAF melanoma cells than in melanocytes ([13] and see Figure S1). These data suggest that if ERK were inhibited in BRAF mutant melanoma cells, MITF protein levels should increase. We tested this using the MEK inhibitor U0126, which efficiently blocked ERK activity in BRAF mutant melanoma cells (Figure 1A). Notably, this resulted in a significant reduction in the proportion of high molecular weight, phosphorylated forms of MITF in the cells (Figure 1A, see *), but surprisingly long-term MEK/ERK inhibition did not lead to an increase in MITF protein as expected, but rather caused an almost complete loss of MITF expression (Figure 1A). Thus, in apparent contradiction to our previous findings, these data suggest that ERK activation is necessary for MITF expression in melanoma cells expressing oncogenic BRAF.
###end p 10
###begin title 11
MITF expression requires BRAF in melanoma cells.
###end title 11
###begin p 12
A) Western blot for MITF, phosphorylated ERK (ppERK) and total ERK2 in untreated (-) melanoma cells or in cells treated with DMSO (D) or U0126 (U0; 10 microM) for 48 h. B) Western blot for BRAF, MITF, ppERK and total ERK2 in melanoma cells 48 h after transfection with control (SC) or BRAF (B1, B2) siRNAs. C) Immunohistochemistry analysis of WM266-4 cells transfected with Alexa-Fluor-647-labelled control (SC) of BRAF siRNA probes (blue). Cells were stained for BRAF or MITF (red) after 48 h and DNA was stained using SYTOX(R)-green (green). D) Quantitative RT-PCR analysis of MITF in A375 and WM266-4 cells 24 and 48 h after transfection with control (SC) or BRAF (B1, B2) siRNA. MITF expression levels are expressed relative to the GAPDH control.
###end p 12
###begin p 13
###xml 155 164 155 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g001">Figure 1B</xref>
###xml 267 276 267 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g001">Figure 1B</xref>
###xml 522 531 522 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g001">Figure 1C</xref>
###xml 596 600 596 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MITF</italic>
###xml 636 645 636 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g001">Figure 1D</xref>
###xml 800 804 800 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Wellbrock2">[13]</xref>
###xml 944 949 944 949 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
To corroborate these findings, we used RNA interference (RNAi) to deplete BRAF in melanoma cell lines. This caused the expected reduction in ERK activity (Figure 1B) and in agreement with the U0126 results described above, also caused a reduction in MITF expression (Figure 1B). To ensure the results above were not a post-extraction artefact, we used an immuno-fluorescence approach, depleting BRAF with fluorescently-labelled siRNA oligonucleotides and this also led to a substantial reduction in nuclear MITF staining (Figure 1C). Furthermore, we found that BRAF depletion resulted in reduced MITF mRNA expression in melanoma cells (Figure 1D). Thus, although we have shown that oncogenic BRAF/ERK signalling suppresses MITF expression by stimulating its degradation through the ubiquitin pathway [13], the data presented here show that this pathway is also required for MITF mRNA expression in these cells. Together these data suggest that V600EBRAF regulates MITF at both the mRNA level and the protein level, so we further examined the role played by BRAF in the regulation of MITF transcription.
###end p 13
###begin title 14
BRAF regulates MITF transcription through BRN2
###end title 14
###begin p 15
###xml 19 23 19 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MITF</italic>
###xml 162 166 162 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MITF</italic>
###xml 195 204 195 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g002">Figure 2A</xref>
###xml 219 224 219 224 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 259 263 259 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MITF</italic>
###xml 306 315 306 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g002">Figure 2B</xref>
###xml 332 337 332 337 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 444 453 444 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g002">Figure 2C</xref>
###xml 557 561 557 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MITF</italic>
###xml 602 606 602 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Levy1">[10]</xref>
###xml 615 624 615 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g002">Figure 2C</xref>
###xml 627 636 627 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In silico</italic>
###xml 800 809 800 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g002">Figure 2D</xref>
###xml 851 855 851 855 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MITF</italic>
First, we examined MITF promoter activity using a luciferase reporter construct. We show that BRAF depletion caused a substantial decrease in the activity of the MITF promoter in melanoma cells (Figure 2A). Conversely, V600EBRAF over-expression activated the MITF promoter, whereas wild-type BRAF did not (Figure 2B). We mapped the V600EBRAF-responsive element(s) to a promoter fragment of -93 to +120 relative to the transcription start site (Figure 2C). This promoter fragment does not contain any elements previously characterized as being important for MITF promoter activity in melanocytic cells ([10] and see Figure 2C). In silico analysis of this fragment () revealed a putative binding site for the POU-domain transcription factor BRN2 at -50 to -36 relative to the transcription start site (Figure 2D), so we investigated the role of BRN2 in MITF regulation in melanoma cells.
###end p 15
###begin title 16
BRAF regulates the MITF promoter through BRN2.
###end title 16
###begin p 17
###xml 3 7 3 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MITF</italic>
###xml 251 255 251 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MITF</italic>
###xml 369 374 369 374 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 391 393 391 393 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 624 628 624 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MITF</italic>
###xml 658 663 658 663 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 767 772 767 772 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 834 838 834 838 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MITF</italic>
###xml 862 866 862 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Levy1">[10]</xref>
###xml 891 895 891 895 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MITF</italic>
###xml 1201 1205 1201 1205 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MITF</italic>
###xml 1251 1260 1251 1260 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cyclin D1</italic>
###xml 1352 1357 1352 1357 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 1682 1687 1682 1687 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
A) MITF (-2293 to +120) promoter activity in A375 cells transfected with control (SC) or BRAF (B1, B2) siRNA. Extracts were prepared after 48 h and analysed for BRAF and ERK2 (loading control) by Western blotting and for luciferase activity [RLU]. B) MITF (-2293 to +120) promoter activity in A375 cells transfected with the indicated amounts (50-500 ng) of myc-tagged V600EBRAF, myc-tagged WTBRAF or an empty vector control (vec). Extracts, prepared 48 h after transfection were analysed for expression of myc-tagged BRAF (*: non-specific band), ERK2 (loading control) by Western blot and for luciferase activity [RLU]. C) MITF promoter activity induced by V600EBRAF. Cells were transfected with the indicated promoter fragments and the fold induction stimulated by V600EBRAF is indicated. Binding sites previously identified in the MITF promoter are indicated [10]. D) The sequence of the MITF promoter from -53 to -27, with the putative BRN2 binding site indicated. The binding site mutations (mut 1 and mut 2) are also shown. E) Chromatin immunoprecipitation (ChIP) assays from A375 cells using BRN2 antibodies, non-specific antibodies (IgG) or no antibody (no Ab). The -170 to +120 region of the MITF promoter was amplified, and as a control the cyclin D1 promoter was also analysed. F) The activity of the -333 luciferase reporter, stimulated by V600EBRAF or BRN2 in A375 cells is shown. The effects of the BRN2 binding site mutations (mut 1, mut 2) are shown, relative (% Activity) to the activity of the non-mutated promoter. G) The activity of the -333 luciferase promoter in A375 cells transfected with control (SC) or BRN2 siRNA is shown. The cells were transfected with V600EBRAF and the reporter construct 24 h after the siRNA had been introduced. Luciferase activity was measured after a further 48 h.
###end p 17
###begin p 18
###xml 59 67 59 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 254 258 254 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MITF</italic>
###xml 287 296 287 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g002">Figure 2E</xref>
###xml 340 349 340 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g002">Figure 2C</xref>
###xml 447 451 447 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MITF</italic>
###xml 484 488 484 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Levy1">[10]</xref>
###xml 524 533 524 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g002">Figure 2F</xref>
###xml 649 666 649 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g002">Figures 2D and 2F</xref>
###xml 697 702 697 702 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 802 811 802 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g002">Figure 2F</xref>
###xml 905 910 905 910 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 1017 1026 1017 1026 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g002">Figure 2G</xref>
BRN2 bound to a fragment (-77 to -20) of the MITF promoter in vitro, but not when the putative BRN2 binding site was mutated (data not shown) and chromatin immunoprecipitation (ChIP) assays showed that endogenous BRN2 binds to the proximal region of the MITF promoter in melanoma cells (Figure 2E). We used the -333 MITF promoter fragment (Figure 2C) for further analysis because it contains all of the elements previously shown to be relevant to MITF regulation in melanocytic cells [10]. BRN2 activated the -333 promoter (Figure 2F), but this activation was significantly reduced when the 5' or 3' region the BRN2 element was mutated (mut1, mut2; Figures 2D and 2F). Importantly, the ability of V600EBRAF to activate the MITF promoter was also dramatically reduced when the BRN2 element was mutated (Figure 2F). This suggested that BRN2 acts downstream of BRAF and in agreement with this hypothesis the V600EBRAF-stimulated activation of the MITF promoter was strongly suppressed when endogenous BRN2 was depleted (Figure 2G).
###end p 18
###begin title 19
###xml 40 45 <span type="species:ncbi:9606">human</span>
BRN2 is required for MITF expression in human melanoma cells
###end title 19
###begin p 20
###xml 34 39 34 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 153 158 153 158 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 163 167 163 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Goodall1">[23]</xref>
###xml 285 294 285 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g003">Figure 3A</xref>
###xml 438 447 438 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g003">Figure 3B</xref>
###xml 557 566 557 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g003">Figure 3C</xref>
The data above place BRN2 between V600EBRAF and MITF in melanoma cells and this is consistent with our previous study showing that BRN2 is downstream of V600EBRAF [23]. Here we confirm that BRN2 expression is dependent on ERK signalling downstream of oncogenic BRAF in melanoma cells (Figure 3A). Furthermore, depletion of endogenous BRN2 reduced the levels of endogenous MITF protein in all melanoma cell lines in which BRAF is mutated (Figure 3B). The decrease in MITF protein was due to reduced MITF mRNA expression as determined by quantitative RT-PCR (Figure 3C) and together these findings clearly demonstrate that in melanoma cells BRN2 is required for MITF expression downstream of oncogenic BRAF.
###end p 20
###begin title 21
BRN2 is required for MITF expression in melanoma cells.
###end title 21
###begin p 22
###xml 753 758 753 758 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 696 701 <span type="species:ncbi:9606">human</span>
A) Western blot for BRN2, ppERK and tubulin (loading control) in WM266-4 cells treated with control (SC), BRAF or ERK2 siRNA. B) Western blot for MITF, BRN2 and total ERK2 (loading control) in the indicated melanoma cells treated with control (SC) or BRN2 siRNA. C) Quantitative real time PCR of MITF mRNA expression in the indicated melanoma cells treated with control (SC) or BRN2 siRNA. MITF expression was normalised to GAPDH expression and is shown as fold expression in reference to SC transfected cells. Results are for one experiment assayed in triplicate. Similar results were obtained in three independent experiments. D) Western blot for BRN2, MITF and total ERK2 (loading control) in human melanoma samples expressing wild-type BRAF (WT) or V600EBRAF (VE). The expression of BRN2 and MITF relative to ERK2 expression is indicated below the blots.
###end p 22
###begin p 23
###xml 138 147 138 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g003">Figure 3D</xref>
###xml 114 119 <span type="species:ncbi:9606">human</span>
Importantly, we show that BRN2 and MITF expression are strongly correlated with the presence of BRAF mutations in human melanoma samples (Figure 3D). These data link mutant BRAF to BRN2 and MITF expression in clinical samples, suggesting that this pathway is essential for progression of BRAF-driven melanomas.
###end p 23
###begin title 24
###xml 44 49 44 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
MITF regulates the cell cycle downstream of V600EBRAF in melanoma cells
###end title 24
###begin p 25
###xml 33 38 33 38 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 82 85 82 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Hingorani1">[6]</xref>
###xml 87 90 87 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Karasarides1">[7]</xref>
###xml 239 248 239 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g004">Figure 4A</xref>
###xml 407 411 407 411 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cip1</sup>
###xml 413 422 413 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g004">Figure 4B</xref>
###xml 437 441 437 441 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cip1</sup>
###xml 504 508 504 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Carreira1">[12]</xref>
###xml 510 514 510 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Du2">[24]</xref>
###xml 574 578 574 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDK4</italic>
###xml 617 626 617 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002734.s002">Figure S2</xref>
Previous studies have shown that V600EBRAF stimulates melanoma cell proliferation [6], [7] and here we show that MITF is required for proliferation in these cells, because MITF depletion blocks DNA synthesis in BRAF mutant melanoma cells (Figure 4A). Commensurate with their roles in proliferation, depletion of BRAF or MITF caused substantial down-regulation of the cell cycle regulators CDK4, CDK2 and p21Cip1 (Figure 4B). CDK2 and p21Cip1 are previously identified MITF target genes in melanoma cells [12], [24] and our data suggest that the melanoma susceptibility gene CDK4 is also an MITF target gene (see also Figure S2).
###end p 25
###begin title 26
MITF acts downstream of BRAF in melanoma cells.
###end title 26
###begin p 27
###xml 19 20 19 20 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 212 215 212 215 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cip</sup>
###xml 967 968 967 968 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
A) DNA synthesis ([3H]-thymidine incorporation) in SKMel28, A375 and WM266-4 cells 48-60 h after transfection with control (SC) or MITF (MI, MI1, MI3) siRNA. B) Western blot for BRAF, MITF, ppERK, CDK4, CDK2, p21Cip (p21) and total ERK2 (loading control) in WM266-4 and A375 cells 24 h and 48 h after transfection with control (SC), BRAF (B1) or MITF (MI, MI1, MI3) siRNA. C) Expression of CDK2 in A375 cells transfected with Alexa-Fluor-647-labelled control (SC) or BRAF siRNA (blue). The cells were microinjected with expression constructs for HA-tagged 4OHT-binding domain of the estrogen receptor (ER) or HA-tagged ER:MITF after 24 hours (green). The cells were treated with 200 nM 4OHT and fixed and stained for CDK2 (red) after a further 40 h. D) Western blot for BRAF, MITF, CDK4, CDK2, ppERK and ERK in A375 cells transfected with control (SC) or BRAF (B1) siRNAs, together with an empty vector (vec) or MITF expression construct (rescue). E) DNA synthesis ([3H]-thymidine incorporation) in A375 cells 40 h after transfection with control (SC) or BRAF (B1) siRNA, together with either an empty vector (vec) or MITF expression construct (rescue). The levels of BRAF expressions are shown on a Western blot with ERK2 serving as the loading control. F) Colony formation assay of SKMel28 cells infected with empty vector (pBabe) or MITF expression construct, and treated with 1 microM PD184352 for 4 weeks. Whole plate and high-magnification images are shown. The inhibitory effect of PD184352 on ERK phosphorylation is shown on a Western blot and actin was used as the loading control.
###end p 27
###begin p 28
###xml 63 67 63 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cip1</sup>
###xml 123 132 123 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g004">Figure 4B</xref>
###xml 350 354 350 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Carreira1">[12]</xref>
###xml 356 360 356 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Wellbrock2">[13]</xref>
###xml 426 435 426 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g004">Figure 4C</xref>
###xml 441 450 441 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g001">Figure 1A</xref>
###xml 601 610 601 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g004">Figure 4D</xref>
###xml 615 624 615 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002734.s003">Figure S3</xref>
###xml 693 702 693 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g004">Figure 4D</xref>
###xml 819 828 819 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g004">Figure 4E</xref>
###xml 872 881 872 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g004">Figure 4F</xref>
Importantly, MITF depletion in melanoma cells blocked CDK2, p21Cip1 and CDK4 expression even though ERK was not inhibited (Figure 4B). Thus we show that not only is MITF regulated by ERK but also that it functions downstream of this signalling pathway. In agreement with this, CDK2 expression was restored when an oestrogen-regulated version of MITF [12], [13] was expressed and activated in cells in which BRAF was depleted (Figure 4C; see Figure 1A for degree of BRAF depletion). Furthermore, CDK2 and CDK4 expression was also restored when full-length MITF was re-expressed in BRAF depleted cells (Figure 4D and Figure S3) and importantly, this occurred in the absence of ERK reactivation (Figure 4D, lane 4). Critically, MITF re-expression rescued proliferation of melanoma cells when BRAF was depleted using RNAi (Figure 4E), or when MEK was inhibited with PD184352 (Figure 4F). These data show that MITF regulates the expression of critical cell cycle regulatory proteins and stimulates melanoma cell proliferation downstream of BRAF in melanoma cells.
###end p 28
###begin title 29
###xml 0 5 0 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 19 21 19 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
V600EBRAF, but not WTBRAF regulates MITF expression in melanocytes
###end title 29
###begin p 30
###xml 41 43 41 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 171 180 171 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g005">Figure 5A</xref>
###xml 270 279 270 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g005">Figure 5B</xref>
###xml 304 313 304 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g005">Figure 5C</xref>
###xml 483 487 483 487 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cip1</sup>
###xml 548 550 548 550 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 569 578 569 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g005">Figure 5D</xref>
###xml 67 72 <span type="species:ncbi:9606">human</span>
We next examined the interaction between WTBRAF and MITF in normal human melanocytes. As in melanoma cells, BRAF and MITF are both essential for melanocyte proliferation (Figure 5A), but in contrast to melanoma cells, MITF expression does not depend on BRAF expression (Figure 5B) or MEK/ERK signalling (Figure 5C) in melanocytes. This is reflected by a functional independence between BRAF and MITF in melanocytes. Whereas MITF depletion caused down-regulation of CDK4, CDK2 and p21Cip1 in melanocytes, these proteins were not down-regulated when WTBRAF was depleted (Figure 5D).
###end p 30
###begin title 31
###xml 0 5 0 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
V600EBRAF can regulate MITF expression in melanocytes.
###end title 31
###begin p 32
###xml 448 451 444 447 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cip</sup>
###xml 870 872 866 868 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 880 885 876 881 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 894 898 890 894 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MITF</italic>
###xml 1028 1033 1024 1029 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 185 190 <span type="species:ncbi:9606">human</span>
###xml 334 339 <span type="species:ncbi:9606">human</span>
###xml 488 493 <span type="species:ncbi:9606">human</span>
###xml 671 676 <span type="species:ncbi:9606">human</span>
A) Thymidine incorporation in normal melanocytes 40 h after transfection with control (SC), BRAF (B1) or MITF siRNA. B) Western blot for BRAF, MITF and ERK2 (loading control) in normal human melanocytes 48 h after transfection with control (SC) or BRAF (B1) siRNA. C) Western blot for MITF, ppERK and ERK2 (loading control) in normal human melanocytes 24 h after treatment with DMSO (D) or U0126 (U0; 10 microM). D) Western blot for CDK4, CDK2, p21Cip (p21) and ERK2 (loading control) in human melanocytes 48 h after transfection with control (SC), BRAF (B1) or MITF (MI) siRNA. E) Western blot for BRN2 and total ERK2 (loading control) in Hela cells (negative control), human melanocytes and the indicated melanoma cell lines carrying mutant BRAF. F) Western blot for BRN2, ppERK and total ERK2 (loading control) in melanocytes transfected with empty vector (control), WTBRAF or V600EBRAF. G) MITF (-2293 to +120) promoter-reporter (luciferase) activity in melanocytes transfected with an empty vector (vec), or with a BRN2 or V600EBRAF expression construct.
###end p 32
###begin p 33
###xml 60 62 60 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 131 140 131 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g005">Figure 5E</xref>
###xml 160 165 160 165 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 213 215 213 215 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 271 280 271 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g005">Figure 5F</xref>
###xml 335 340 335 340 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 371 375 371 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MITF</italic>
###xml 386 395 386 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g005">Figure 5G</xref>
###xml 427 429 427 429 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 458 463 458 463 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 654 659 654 659 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 697 706 697 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g003">Figure 3A</xref>
###xml 792 796 792 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Wellbrock2">[13]</xref>
One possible explanation for the lack of MITF regulation by WTBRAF is that unlike melanoma cells, melanocytes do not express BRN2 (Figure 5E). Notably, whereas V600EBRAF can induce BRN2 expression in melanocytes, WTBRAF does not stimulate BRN2 expression in these cells (Figure 5F). Importantly, when introduced into melanocytes, both V600EBRAF and BRN2 can activate the MITF promoter (Figure 5G). Thus in melanocytes although WTBRAF does not regulate MITF, V600EBRAF can induce expression of BRN2, allowing it to induce MITF transcription. Notably, the induction of BRN2 through MEK and ERK in melanoma cells appears to be fundamental to the ability of V600EBRAF to regulate MITF in these cells (Figure 3A). Thus, we have established that in addition to regulating MITF at the protein level [13], oncogenic BRAF also regulates MITF at the level of gene transcription in melanocytic cells.
###end p 33
###begin title 34
Discussion
###end title 34
###begin p 35
###xml 28 33 28 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 292 296 292 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Cook1">[25]</xref>
###xml 414 418 414 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Thomson1">[26]</xref>
###xml 569 573 569 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Goodall1">[23]</xref>
###xml 663 672 663 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g005">Figure 5F</xref>
###xml 784 788 784 788 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MITF</italic>
###xml 979 988 979 988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g003">Figure 3D</xref>
###xml 955 960 <span type="species:ncbi:9606">human</span>
In this study, we show that V600EBRAF regulates the MITF promoter through the octamer-binding transcription factor BRN2 (N-Oct-3). BRN2 is a neuronal-specific protein that is expressed in developing melanoblasts, but which becomes down-regulated as these cells differentiate into melanocytes [25]. Importantly, BRN2 is reactivated in melanoma cells and becomes essential for their proliferation and tumourigenesis [26]. Thus BRN2 re-expression is important for melanoma progression and we have previously shown that BRN2 is a target of oncogenic BRAF in melanoma cells [23]. Here we show that BRN2 expression can also be induced by oncogenic BRAF in melanocytes (Figure 5F). We further demonstrate that BRN2 induces MITF transcription through a binding site located at -50/-36 of the MITF promoter, linking MITF expression to oncogenic BRAF through BRN2. Consistent with this, we show that BRN2 and MITF expression occur coincident with oncogenic BRAF in human melanoma samples (Figure 3D). Importantly, we show that wild type BRAF does not induce BRN2 expression in melanocytes, and neither does it stimulate MITF transcription in melanocytes or melanoma cells. Together, these data show that the ability of BRAF to regulate MITF expression is a newly acquired function of the oncogenic protein and that this is mediated through its ability to induce expression of BRN2.
###end p 35
###begin p 36
###xml 41 46 41 46 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 77 81 77 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mitf</italic>
###xml 112 116 112 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Wellbrock2">[13]</xref>
###xml 150 155 150 155 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 240 249 240 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002734.s004">Figure S4</xref>
###xml 522 527 522 527 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 855 860 855 860 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 900 904 900 904 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MITF</italic>
###xml 94 99 <span type="species:ncbi:10090">mouse</span>
###xml 207 212 <span type="species:ncbi:10090">mouse</span>
###xml 335 340 <span type="species:ncbi:10090">mouse</span>
###xml 345 350 <span type="species:ncbi:9606">human</span>
###xml 405 411 <span type="species:ncbi:9606">humans</span>
###xml 472 477 <span type="species:ncbi:10090">mouse</span>
###xml 570 575 <span type="species:ncbi:10090">mouse</span>
###xml 614 619 <span type="species:ncbi:10090">mouse</span>
###xml 811 816 <span type="species:ncbi:9606">human</span>
Importantly, we previously reported that V600EBRAF suppresses the endogenous mitf promoter in mouse melanocytes [13]. In line with this, we find that V600EBRAF also suppresses the promoter when expressed in mouse melanoma cells (B16 cells, Figure S4). This suggests that the MITF promoter is regulated differently by oncogenic BRAF in mouse and human cells, but it should be mentioned that in contrast to humans, somatic mutations in BRAF do not appear to be a feature of mouse melanomas. Interestingly, we find that like V600EBRAF, BRN2 suppresses the MITF promoter in mouse cells (not shown), suggesting that in mouse cells the presence or absence of certain co-factors might modulate the outcome of the action of BRN2 on the MITF promoter. In summary, we have shown that BRN2 induces MITF mRNA expression in human melanoma cells and that through BRN2, V600EBRAF can stimulate transcription of the MITF gene in both melanoma cells and melanocytes.
###end p 36
###begin p 37
###xml 187 191 187 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Hemesath1">[21]</xref>
###xml 193 197 193 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Wu1">[22]</xref>
###xml 333 337 333 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Wellbrock2">[13]</xref>
###xml 346 355 346 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002734.s005">Figure S5</xref>
###xml 519 528 519 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002734.s001">Figure S1</xref>
###xml 565 570 565 570 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 583 587 583 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MITF</italic>
###xml 796 800 796 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Wellbrock2">[13]</xref>
###xml 809 813 809 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Carreira2">[27]</xref>
###xml 955 963 955 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g006">Figure 6</xref>
###xml 1036 1040 1036 1040 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Levy1">[10]</xref>
###xml 1133 1137 1133 1137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Wellbrock2">[13]</xref>
###xml 1173 1177 1173 1177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Carreira2">[27]</xref>
It has previously been shown that MITF activation and degradation are coupled because ERK phosphorylation both activates MITF and targets it for degradation through the ubiquitin pathway [21], [22]. Importantly, we demonstrated that because ERK is constitutively activated in BRAF mutant melanoma cells, MITF is constantly degraded ([13] and see Figure S5), a finding that is in agreement with the observation that MITF protein levels are generally lower in BRAF mutant melanoma cell lines than in primary melanocytes (Figure S1). Thus, our demonstration here that V600EBRAF induces MITF transcription appears at first to be counter-intuitive. However, MITF plays a critical role in pigment cell behaviour and as previously described, this is partly controlled by the level of MITF in the cells ([13] and see [27]). High levels of MITF trigger cell cycle arrest and differentiation, whereas low levels of activity trigger cell cycle arrest and death (see Figure 6). Thus, MITF has both tumour promoting and tumour inhibitory activities [10] and its ability to control cell fate decisions appears to depend on it levels of expression [13] or possibly its levels of activity [27].
###end p 37
###begin title 38
A model of MITF regulation by oncogenic BRAF in melanoma cells.
###end title 38
###begin p 39
###xml 300 305 300 305 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 528 533 528 533 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
MITF protein levels are critical in melanoma cells. High levels of MITF stimulate differentiation, whereas if the levels are too low, the cells die by apoptosis. Therefore to stimulate proliferation in melanoma cells, MITF protein levels must be constrained to within a narrow range. We propose that V600EBRAF stimulates MITF activation through ERK phosphorylation, but this targets MITF for degradation. This would reduce MITF protein to levels that are below those required for survival and proliferation, so to counter this, V600EBRAF stimulates MITF transcription through up-regulation of BRN2. Thus although MITF is constantly destroyed by proteasome-mediated degradation, its expression persists at a level that is sufficient to maintain expression of cell cycle components such as CDK4 and CDK2 and survival factors such as BCL2, thereby favouring proliferation and survival over differentiation or apoptosis.
###end p 39
###begin p 40
###xml 93 97 90 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Massague1">[28]</xref>
###xml 329 337 326 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g006">Figure 6</xref>
###xml 827 835 824 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g006">Figure 6</xref>
###xml 911 915 908 912 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MITF</italic>
###xml 928 933 925 930 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 1027 1031 1024 1028 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MITF</italic>
###xml 1098 1102 1095 1099 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 1114 1118 1111 1115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Garraway2">[20]</xref>
###xml 1198 1202 1195 1199 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MITF</italic>
###xml 1234 1238 1231 1235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Garraway2">[20]</xref>
###xml 1308 1317 1305 1314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002734-g001">Figure 1B</xref>
Thus MITF is akin to TGFbeta, which, is also either a tumour promoter or a tumour suppressor [28] and we propose that MITF expression/activity must be carefully regulated in melanoma cells to ensure that the levels are not so low as to cause cell death but equally, not so high as to cause cell cycle arrest and differentiation (Figure 6). Our data suggest that oncogenic BRAF plays a key role in regulating MITF to ensure that this is achieved and together with our previous observations, these studies demonstrate that the regulation of MITF by oncogenic BRAF is complex and multifaceted. We posit that because constitutively active ERK is so efficient at down-regulating MITF in BRAF mutant melanoma cells, it is necessary for the cells to rescue MITF expression to ensure that they can continue to proliferate and survive (Figure 6). One strategy that the cells use to achieve this is the activation of the MITF promoter by V600EBRAF/ERK/BRN2 as described here. Another strategy appears to be gene amplification, since the MITF gene is amplified in approximately 15% of melanoma cases in which BRAF is mutated [20]. Notably however, these strategies are not mutually exclusive because although MITF is amplified in SKMel-28 cells [20], MITF expression still depends on oncogenic BRAF in these cells (see Figure 1B).
###end p 40
###begin p 41
###xml 360 365 <span type="species:ncbi:9606">human</span>
In summary, we show that oncogenic BRAF plays a critical role in regulating MITF expression in melanoma cells, using apparently opposing mechanisms to exquisitely regulate the levels of this critical transcription factor. This ensures that the levels of MITF are optimal for tumour progression and suggests one reason for why BRAF is such a potent oncogene in human melanoma.
###end p 41
###begin title 42
Materials and Methods
###end title 42
###begin title 43
Cell biology approaches
###end title 43
###begin p 44
###xml 156 159 156 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Wellbrock1">[5]</xref>
###xml 212 231 212 231 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">AGAAUUGGAUCUGGAUCAU</named-content>
###xml 237 256 237 256 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">CAGUCUACAAGGGAAAGUG</named-content>
###xml 276 297 276 297 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">GCGCAGAGCCUGGUGCAGGUU</named-content>
###xml 307 328 307 328 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">CCGCAGCGUCUAACCACUAUU</named-content>
###xml 339 358 339 358 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">GAACGAAGAAGAAGAUUUA</named-content>
###xml 369 388 369 388 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">GACCUAACCUGUACAACAA</named-content>
###xml 399 420 399 420 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">CUCCAAAGCUCUGGACUUAUU</named-content>
###xml 500 501 500 501 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 588 589 584 585 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 718 719 710 711 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 71 76 <span type="species:ncbi:9606">human</span>
Culture and transfection and in vitro analysis of melanoma cell lines, human melanocytes, stable melanocyte lines and the MITF siRNA MI have been described [5]. Further siRNA oligonucleotides were. For BRAF: B1: AGAAUUGGAUCUGGAUCAU; B2: CAGUCUACAAGGGAAAGUG, for BRN2: BRN2-1: GCGCAGAGCCUGGUGCAGGUU; BRN2-2: CCGCAGCGUCUAACCACUAUU; for MI1: GAACGAAGAAGAAGAUUUA; for MI3: GACCUAACCUGUACAACAA for ERK2: CUCCAAAGCUCUGGACUUAUU. U0126 was from Promega. For thymidine incorporation cells were incubated with 3H-thymidine (0.4 microCi/ml) for 4 h before analysis. For the MEK inhibition rescue, 106 SKMel-28 cells were infected with pBABEpuro or pBABEpuro-MITF viruses, selected with 2 microg/ml puromycin for 48 hours and 5x104 of the remaining cells were plated in 10 cm dishes and incubated with 1 microM PD184352 for 4 weeks before being fixed, stained and photographed. The antibodies used were: MITF: C5 and D5 (Neomarkers and generously provided by D. Fisher); BRAF: F-7; Santa Cruz; phospho-ERK: MAPK-YT (Sigma); anti-myc (Abcam); ERK2: C-14 (Santa Cruz); CDK2: M2 (Santa Cruz); CDK4: C-22 (Santa Cruz); BRN2: C-20 (Santa Cruz); p21 (TDL).
###end p 44
###begin title 45
Immunofluorescence
###end title 45
###begin p 46
Fixed cells transfected with Alexa-Fluor-647-labelled siRNA probes were incubated with the appropriate primary and Cy3-conjugated secondary antibodies (Dianova). Nuclei were counterstained with SYTOX(R)-green, and HA-tagged ER or ER:MITF were detected with fluorescein-coupled anti-HA antibody 3F10 (Roche).
###end p 46
###begin title 47
Reverse transcriptate-PCR and Chromatin-immunoprecipitation
###end title 47
###begin p 48
###xml 146 150 144 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MITF</italic>
###xml 152 172 150 170 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">CCGTCTCTCACTGGATTGGT</named-content>
###xml 174 194 172 192 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">TACTTGGTGGGGTTTTCGAG</named-content>
###xml 196 201 194 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 203 223 201 221 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">CAATGACCCCTTCATTGACC</named-content>
###xml 225 245 223 243 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">GACAAGCTTCCCGTTCTCAG</named-content>
###xml 366 370 364 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MITF</italic>
###xml 381 412 379 410 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">CGTCACTTAAAAAGGTACCTTTATATTTATG</named-content>
###xml 414 447 412 445 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">TGTTTTAGCTAGCACCAATCCAGTGAGAGACGG</named-content>
###xml 449 458 447 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cyclin D1</italic>
###xml 469 491 467 489 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">AACAAAACCAATTAGGAACCTT</named-content>
###xml 493 515 491 513 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">ATTTCCTTCATCTTGTCCTTCT</named-content>
RNA was isolated with TRIZOL(R) and selected genes were amplified by quantitative real time PCR using SYBR green (Qiagen). Primers sequences were MITF: CCGTCTCTCACTGGATTGGT, TACTTGGTGGGGTTTTCGAG; GAPDH: CAATGACCCCTTCATTGACC, GACAAGCTTCCCGTTCTCAG. Chromatin immunoprecipitation (ChIP) assays were performed with IMGENEX reagents as recommended. Primer sequences were MITF promoter: CGTCACTTAAAAAGGTACCTTTATATTTATG, TGTTTTAGCTAGCACCAATCCAGTGAGAGACGG; cyclin D1 promoter: AACAAAACCAATTAGGAACCTT, ATTTCCTTCATCTTGTCCTTCT.
###end p 48
###begin title 49
Luciferase Reporter Constructs and Assays
###end title 49
###begin p 50
###xml 9 14 9 14 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 95 98 95 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002734-Wan1">[4]</xref>
###xml 128 132 128 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MITF</italic>
###xml 417 422 409 414 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
BRAF and V600EBRAF expression constructs are described and BRN2 was expressed using pEFPlink.6 [4]. Approximately 2.3 kb of the MITF promoter (-2293 to +120) and the various truncated promoters were cloned into pGL2 (Promega). Mutant promoter constructs (mut1, mut2) were generated by PCR directed mutagenesis. Cells were transfected with 0.6 microg of the indicated promoter-reporter constructs, 0.3 microg of BRAF, V600EBRAF or BRN2 expression constructs and 0.3 microg of pSV-ss-Galactosidase (Promega) using Lipofectamine (Gibco). Cells were analysed for luciferase activity after 48 h using RLB buffer (Promega). The data were corrected for b-galactosidase and represent the activity for assays performed in triplicate, with error bars to represent standard deviations from the mean. All experiments were performed a minimum of 3 times.
###end p 50
###begin title 51
Supporting Information
###end title 51
###begin p 52
###xml 62 67 <span type="species:ncbi:9606">Human</span>
Melanoma cells express lower levels of MITF than melanocytes. Human melanocytes and melanoma cells expressing oncogenic BRAF were analysed for MITF expression. ERK2 served as loading control.
###end p 52
###begin p 53
(0.24 MB TIF)
###end p 53
###begin p 54
Click here for additional data file.
###end p 54
###begin p 55
MITF regulates CDK2 and CDK4 transcription. CDK4 expression is regulated by MITF in melanoma cells. (A) RT-PCR for CDK4 and CDK2 (control) in A375 and WM266-4 cells transfected with either control (SC) or MITF (MI) siRNAs. Cells were analysed 24 and 48 hours after transfection and GAPDH serves as a loading control. (B) Real-time RT-PCR for CDK4 in A375 and WM266-4 cells transfected with either control (SC) or MITF (MI) siRNAs. Cells were analysed 24 and 48 hours after transfection. CDK4 expression is shown as fold expression in reference to SC transfected cells and relative to GAPDH expression.
###end p 55
###begin p 56
(0.47 MB TIF)
###end p 56
###begin p 57
Click here for additional data file.
###end p 57
###begin p 58
MITF regulates CDK2 and CDK4 transcription downstream of oncogenic BRAF. Quantification of CDK2 and CDK4 expresssion. A375 cells transfected with control (SC) or BRAF (B1) siRNAs, together with an empty vector (vec) or an MITF expression construct (rescue) were analysed for CDK2 and CDK4 and the expression was quantified using ImageQuant (Amersham, GE-Healthcare).
###end p 58
###begin p 59
(0.24 MB TIF)
###end p 59
###begin p 60
Click here for additional data file.
###end p 60
###begin p 61
###xml 47 52 <span type="species:ncbi:10090">mouse</span>
###xml 111 116 <span type="species:ncbi:10090">mouse</span>
###xml 162 167 <span type="species:ncbi:10090">mouse</span>
###xml 339 344 <span type="species:ncbi:9606">human</span>
Oncogenic BRAF suppresses the MITF promoter in mouse melanoma cells. V600EBRAF suppresses the MITF promoter in mouse melanoma cells. (A) Luciferase assay for the mouse MITF promoter activity in B16 cells transfected with vector (vec) or V600EBRAF as indicated. The cells were analysed 48 h after transfection. (B) Luciferase assay for the human MITF promoter activity in B16 cells transfected with vector (vec) or V600EBRAF as indicated.
###end p 61
###begin p 62
(0.35 MB TIF)
###end p 62
###begin p 63
Click here for additional data file.
###end p 63
###begin p 64
###xml 114 119 <span type="species:ncbi:9606">human</span>
Oncogenic BRAF suppresses MITF protein expression. Oncogenic BRAF suppresses MITF protein levels. Western blot of human melanocytes transfected with V600EBRAF or an empty vector. Cells were analysed for myc-tagged V600EBRAF, MITF and ppERK. ERK2 was used as loading control.
###end p 64
###begin p 65
(0.21 MB TIF)
###end p 65
###begin p 66
Click here for additional data file.
###end p 66
###begin p 67
We thank D. Fisher for the C5 MITF-antibody and D. Meijer for pCMV.BRN2. We also thank Tanya Ahmad, Tim Eisen and Martin Gore for the melanoma tumour samples.
###end p 67
###begin title 68
References
###end title 68
###begin article-title 69
The hallmarks of cancer.
###end article-title 69
###begin article-title 70
###xml 53 58 <span type="species:ncbi:9606">human</span>
Lineage dependency and lineage-survival oncogenes in human cancer.
###end article-title 70
###begin article-title 71
###xml 30 35 <span type="species:ncbi:9606">human</span>
Mutations of the BRAF gene in human cancer.
###end article-title 71
###begin article-title 72
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.
###end article-title 72
###begin article-title 73
V599EB-RAF is an Oncogene in Melanocytes.
###end article-title 73
###begin article-title 74
###xml 30 35 <span type="species:ncbi:9606">human</span>
Suppression of BRAF(V599E) in human melanoma abrogates transformation.
###end article-title 74
###begin article-title 75
B-RAF is a therapeutic target in melanoma.
###end article-title 75
###begin article-title 76
Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.
###end article-title 76
###begin article-title 77
Oncogenic BRAF is required for tumor growth and maintenance in melanoma models.
###end article-title 77
###begin article-title 78
MITF: master regulator of melanocyte development and melanoma oncogene.
###end article-title 78
###begin article-title 79
MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A.
###end article-title 79
###begin article-title 80
Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression.
###end article-title 80
###begin article-title 81
Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation.
###end article-title 81
###begin article-title 82
###xml 21 26 <span type="species:ncbi:9606">human</span>
In vivo switching of human melanoma cells between proliferative and invasive states.
###end article-title 82
###begin article-title 83
Micropthalmia transcription factor: a new prognostic marker in intermediate-thickness cutaneous malignant melanoma.
###end article-title 83
###begin article-title 84
###xml 100 105 <span type="species:ncbi:9606">human</span>
The melanocyte-specific isoform of the microphthalmia transcription factor affects the phenotype of human melanoma.
###end article-title 84
###begin article-title 85
Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma.
###end article-title 85
###begin article-title 86
Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF.
###end article-title 86
###begin article-title 87
Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability.
###end article-title 87
###begin article-title 88
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.
###end article-title 88
###begin article-title 89
MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes.
###end article-title 89
###begin article-title 90
c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi.
###end article-title 90
###begin article-title 91
The Brn-2 transcription factor links activated BRAF to melanoma proliferation.
###end article-title 91
###begin article-title 92
MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma.
###end article-title 92
###begin article-title 93
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human melanoblasts in culture: expression of BRN2 and synergistic regulation by fibroblast growth factor-2, stem cell factor, and endothelin-3.
###end article-title 93
###begin article-title 94
###xml 80 85 <span type="species:ncbi:9606">human</span>
The brn-2 gene regulates the melanocytic phenotype and tumorigenic potential of human melanoma cells.
###end article-title 94
###begin article-title 95
Mitf regulation of Dia1 controls melanoma proliferation and invasiveness.
###end article-title 95
###begin article-title 96
The logic of TGFbeta signaling.
###end article-title 96
###begin p 97
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 97
###begin p 98
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was funded by Cancer Research UK (Ref C107/A3096) and The Institute of Cancer Research. The funders played no role in the experiment design, execution, analysis or preperation of the paper.
###end p 98

